Core Viewpoint - The Financial Regulatory Bureau has revised the "Management Measures for Trust Companies," which will take effect on January 1, 2026, focusing on core responsibilities, risk prevention, and enhancing corporate governance in the trust industry [1][2]. Group 1: Key Revisions - The revised measures emphasize the core business of trust companies, clarifying their roles as trustees and regulating asset service trusts, asset management trusts, and charitable trusts [1][4]. - The principle of "seller responsibility, buyer risk" is reinforced, breaking the rigid repayment structure [1][4]. - Trust companies are required to deepen the integration of party building and corporate governance, enhancing shareholder behavior and related party transaction management [1][4]. Group 2: Risk Management and Governance - Trust companies must strengthen comprehensive risk management, focusing on compliance and operational risks throughout the trust business process [1][22]. - The minimum registered capital for trust companies will be increased, and there will be stricter capital and provision management requirements [1][22]. - A scientific internal assessment and incentive mechanism must be established to maximize the legitimate interests of beneficiaries [1][19]. Group 3: Regulatory Requirements - The measures specify enhanced regulatory requirements, including behavior supervision and penetrating regulation, to improve risk disposal and market exit mechanisms [1][22][45]. - Trust companies are required to establish a recovery and disposal plan mechanism, which must be updated regularly and approved by the regulatory authority [1][50]. - The regulatory authority will implement a tiered and classified supervision approach based on the risk status and systemic impact of trust companies [1][61].

Core Viewpoint - The article discusses the tightening regulations on medical advertising in response to the increasing prevalence of misleading advertisements disguised as health information, particularly in the context of the internet's rapid development [1][3]. Summary by Sections Medical Advertising Regulation Challenges - Medical advertising has become more complex with the rise of the internet, leading to a blurring of lines between health education and advertising [1]. - In the first half of the year, regulatory authorities handled 1,666 cases of illegal medical advertising, imposing fines totaling 12.78 million yuan [1]. Introduction of the Recognition Guidelines - The State Administration for Market Regulation, in collaboration with the National Health Commission and the National Administration of Traditional Chinese Medicine, has developed the "Medical Advertising Recognition Guidelines" to clarify what constitutes medical advertising [3][4]. - The guidelines emphasize the importance of legitimate advertising entities and aim to address issues related to unqualified "black hospitals" and "black doctors" misleading the public [3]. Key Changes in the Guidelines - The guidelines prohibit any entity or individual, except legally established medical institutions, from publishing medical advertisements [4]. - The previous ambiguous definitions regarding promotional activities and health education have been removed, tightening the criteria for what constitutes advertising [4]. - The guidelines specify that linking health education content to medical services or products constitutes disguised advertising [4]. Focus on Internet Platforms - The rise of internet platforms has increased the volume of medical advertising, making it difficult for consumers to distinguish between advertising and educational content [6]. - Recent policies in Beijing aim to enhance compliance and promote legal awareness regarding medical advertising on digital platforms [6]. Collaborative Regulatory Efforts - The guidelines call for a coordinated approach among various regulatory bodies to effectively manage medical advertising [8]. - Local market supervision bureaus are collaborating with health and law enforcement departments to create a comprehensive regulatory network [8]. - A tiered regulatory approach is being implemented to avoid one-size-fits-all enforcement, allowing for leniency in minor violations [8].

Core Viewpoint - The regulatory authority emphasizes the need for life insurance companies to enhance the sustainability of dividend insurance operations and protect consumer rights by adhering to asset-liability management principles [1][2][4]. Group 1: Regulatory Requirements - Companies are required to balance the predetermined interest rates of dividend insurance with floating returns and actual dividend realization rates, considering the asset allocation characteristics and actual investment returns of each account [2]. - The regulatory body will strengthen data monitoring and impose measures such as regulatory interviews, orders for rectification, and rating deductions for non-compliance [2][6]. Group 2: Dividend Insurance Overview - Dividend insurance refers to life insurance products where companies distribute a portion of their operating surplus to policyholders [3]. - In a long-term declining interest rate environment, insurance companies are increasing the sales of dividend insurance, making dividend levels a competitive focus in the industry [4]. Group 3: Industry Analysis - The new standards are clear and emphasize the regulation and sustainability of dividends, which is beneficial for the long-term healthy development of the dividend insurance sector amid company transformations [5]. - Last year, the overall dividend level for most life insurance companies ranged between 3% and 3.2% [8].